Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Voyager Therapeutics (VYGR) reported a Q3 loss of $0.16 per share, which is better than the Zacks Consensus Estimate of a $0.45 loss. This is an improvement from the $0.59 loss per share a year ago.
November 12, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Voyager Therapeutics reported a Q3 loss of $0.16 per share, better than the expected $0.45 loss, and an improvement from last year's $0.59 loss.
The better-than-expected earnings report is likely to have a positive impact on VYGR's stock price in the short term. The improvement from last year's loss also indicates positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100